ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ASND • US04351P1012

226.1 USD
+2.15 (+0.96%)
At close: Jan 30, 2026
226.1 USD
0 (0%)
After Hours: 1/30/2026, 8:00:01 PM
Fundamental Rating

3

ASND gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of ASND have multiple concerns. ASND is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ASND had negative earnings in the past year.
  • In the past year ASND has reported a negative cash flow from operations.
  • In the past 5 years ASND always reported negative net income.
  • In the past 5 years ASND always reported negative operating cash flow.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.17%, ASND is in the better half of the industry, outperforming 76.38% of the companies in the same industry.
Industry RankSector Rank
ROA -20.17%
ROE N/A
ROIC N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

  • ASND's Gross Margin of 86.80% is amongst the best of the industry. ASND outperforms 89.33% of its industry peers.
  • ASND's Gross Margin has improved in the last couple of years.
  • ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

2

2. Health

2.1 Basic Checks

  • ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ASND has been increased compared to 1 year ago.
  • The number of shares outstanding for ASND has been increased compared to 5 years ago.
  • ASND has a better debt/assets ratio than last year.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ASND has an Altman-Z score of 2.11. This is not the best score and indicates that ASND is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.11, ASND is doing good in the industry, outperforming 67.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.11
ROIC/WACCN/A
WACC7.05%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • ASND has a Current Ratio of 1.03. This is a normal value and indicates that ASND is financially healthy and should not expect problems in meeting its short term obligations.
  • ASND has a worse Current ratio (1.03) than 85.71% of its industry peers.
  • A Quick Ratio of 0.73 indicates that ASND may have some problems paying its short term obligations.
  • ASND has a worse Quick ratio (0.73) than 88.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.73
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.33% over the past year.
  • The Revenue has grown by 97.46% in the past year. This is a very strong growth!
  • ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 93.57% yearly.
EPS 1Y (TTM)48.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.86%
Revenue 1Y (TTM)97.46%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%269.4%

3.2 Future

  • ASND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.49% yearly.
  • ASND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.15% yearly.
EPS Next Y48.58%
EPS Next 2Y58.62%
EPS Next 3Y50.07%
EPS Next 5Y39.49%
Revenue Next Year128.4%
Revenue Next 2Y105.07%
Revenue Next 3Y82.16%
Revenue Next 5Y57.15%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 20 30

2

4. Valuation

4.1 Price/Earnings Ratio

  • ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 55.95 indicates a quite expensive valuation of ASND.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ASND indicates a rather cheap valuation: ASND is cheaper than 89.71% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of ASND to the average of the S&P500 Index (25.57), we can say ASND is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 55.95
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • ASND's earnings are expected to grow with 50.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.62%
EPS Next 3Y50.07%

0

5. Dividend

5.1 Amount

  • ASND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ASCENDIS PHARMA A/S - ADR / ASND FAQ

Can you provide the ChartMill fundamental rating for ASCENDIS PHARMA A/S - ADR?

ChartMill assigns a fundamental rating of 3 / 10 to ASND.


What is the valuation status for ASND stock?

ChartMill assigns a valuation rating of 2 / 10 to ASCENDIS PHARMA A/S - ADR (ASND). This can be considered as Overvalued.


What is the profitability of ASND stock?

ASCENDIS PHARMA A/S - ADR (ASND) has a profitability rating of 2 / 10.


How financially healthy is ASCENDIS PHARMA A/S - ADR?

The financial health rating of ASCENDIS PHARMA A/S - ADR (ASND) is 2 / 10.